» Articles » PMID: 28003281

DNMT3A in Leukemia

Overview
Specialty General Medicine
Date 2016 Dec 23
PMID 28003281
Citations 90
Authors
Affiliations
Soon will be listed here.
Abstract

DNA methylation is an epigenetic process involved in development, aging, and cancer. Although the advent of new molecular techniques has enhanced our knowledge of how DNA methylation alters chromatin and subsequently affects gene expression, a direct link between epigenetic marks and tumorigenesis has not been established. DNMT3A is a de novo DNA methyltransferase that has recently gained relevance because of its frequent mutation in a large variety of immature and mature hematologic neoplasms. DNMT3A mutations are early events during cancer development and seem to confer poor prognosis to acute myeloid leukemia (AML) patients making this gene an attractive target for new therapies. Here, we discuss the biology of DNMT3A and its role in controlling hematopoietic stem cell fate decisions. In addition, we review how mutant DNMT3A may contribute to leukemogenesis and the clinical relevance of DNMT3A mutations in hematologic cancers.

Citing Articles

The Fetal Environment and the Development of Hypertension-The Epigenetic Modification by Glucocorticoids.

Mori F, Shimosawa T Int J Mol Sci. 2025; 26(1.

PMID: 39796274 PMC: 11720225. DOI: 10.3390/ijms26010420.


Increased local DNA methylation disorder in AMLs with DNMT3A-destabilizing variants and its clinical implication.

Lee D, Koo B, Kim S, Byun J, Hong J, Shin D Nat Commun. 2025; 16(1):560.

PMID: 39794314 PMC: 11724044. DOI: 10.1038/s41467-024-55691-z.


Acute Myeloid Leukemia with Normal Cytogenetics and -Mutation: Impact of Mutation Topography on Outcomes.

Zhao M, Liao M, Gale R, Zhang M, Wu L, Yan N Biomedicines. 2025; 12(12.

PMID: 39767827 PMC: 11673242. DOI: 10.3390/biomedicines12122921.


Biological Markers of Myeloproliferative Neoplasms in Children, Adolescents and Young Adults.

Ozygala A, Rokosz-Mierzwa J, Widz P, Skowera P, Wilinski M, Styka B Cancers (Basel). 2024; 16(23).

PMID: 39682300 PMC: 11640741. DOI: 10.3390/cancers16234114.


Clonal hematopoiesis and hematological malignancy.

Dunn W, McLoughlin M, Vassiliou G J Clin Invest. 2024; 134(19).

PMID: 39352393 PMC: 11444162. DOI: 10.1172/JCI180065.


References
1.
Robertson K, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales F . The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999; 27(11):2291-8. PMC: 148793. DOI: 10.1093/nar/27.11.2291. View

2.
Xie S, Wang Z, Okano M, Nogami M, Li Y, He W . Cloning, expression and chromosome locations of the human DNMT3 gene family. Gene. 1999; 236(1):87-95. DOI: 10.1016/s0378-1119(99)00252-8. View

3.
Okano M, BELL D, Haber D, Li E . DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999; 99(3):247-57. DOI: 10.1016/s0092-8674(00)81656-6. View

4.
Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y . Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001; 97(5):1172-9. DOI: 10.1182/blood.v97.5.1172. View

5.
Lin I, Han L, Taghva A, OBrien L, Hsieh C . Murine de novo methyltransferase Dnmt3a demonstrates strand asymmetry and site preference in the methylation of DNA in vitro. Mol Cell Biol. 2002; 22(3):704-23. PMC: 133553. DOI: 10.1128/MCB.22.3.704-723.2002. View